Ignite Creation Date:
2025-12-25 @ 3:28 AM
Ignite Modification Date:
2025-12-26 @ 2:08 AM
Study NCT ID:
NCT03768505
Status:
TERMINATED
Last Update Posted:
2024-12-31
First Post:
2018-12-04
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
Sponsor:
MEI Pharma, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-06-25
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-24
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-03-24
Completion Date Type:
ACTUAL
First Submit Date:
2018-12-04
First Submit QC Date:
None
Study First Post Date:
2018-12-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-12-05
Results First Submit QC Date:
None
Results First Post Date:
2024-02-01
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-12-29
Last Update Post Date:
2024-12-31
Last Update Post Date Type:
ACTUAL